Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In HCC-INT, the CD133 positive rate in the INT component (83.3%) was significantly higher than the HCC component (8.3%) (P=0.001).
|
31661725 |
2020 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
|
31042624 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype.
|
30959553 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that Cygb is significantly deregulated in human hepatocellular carcinoma (HCC) tissue and its decrease aggravates the growth of liver cancer stem cells (LCSCs) and increases the subpopulation of CD133(+) LCSCs.
|
30365183 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> The study indicates that secretory factors like TGF-β from neighboring endothelial cells may enhance expression of CD133 and impart an aggressive EMT phenotype to HBx-infected hepatoma cells in HBV induced HCC.
|
31069171 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notably, docetaxel‑inhibited SOX2 expression and growth of human CD133‑expressing HCC stem cells were partially restricted following the block of the PI3K/AKT signaling pathway using the inhibitor LY294002.
|
30483804 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the proportion of CD44+/CD133+ HCC cancer stem cells (CSCs) was significantly greater in cells cultured on scaffolds than in those grown in 2D cultures.
|
30302811 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, whether AQP3 acted as an oncogenic gene in HCC and maintained the stemness of CD133+ hepatoma cells were elucidated; also, a novel mechanism underlying the AQP3/STAT3/CD133 pathway in HCC was deduced.
|
31197130 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133<sup>+</sup> HCC.
|
31226288 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both HOXA11-AS silencing and HOXA11 overexpression suppressed the self-renewal, proliferation, migration, and tumorigenicity of HCC stem cells in vivo, as evidenced by the decreased expression of cancer stem cell surface markers (CD133 and CD44) and stemness-related transcription factors (Nanog, Sox2, and Oct4).
|
31757938 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the statistical association and the diagnostic efficacies of TIPRL, LC3 and CD133 in HCC tissues were confirmed in a different IHC cohort.
|
31727942 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells.
|
31066542 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the stem cell markers CD24 and CD133 in the tumors of patients with HCC was associated with greater iNOS expression and worse outcomes.
|
30297396 |
2018 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on CD133 immunostaining and serum AFP levels, the HCC cases were subclassified into four subtypes, which demonstrated different clinicopathological features and varying prognoses.
|
29435028 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strikingly, Anti-CD147 ILs-DOX reduced the CD133-positive fraction of HCC cells, suggesting its potential in reducing the number of HCC stem cells.
|
29045824 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRPV2 expression at protein levels revealed converse correlation with those of CD133 and CD44 in human hepatocellular carcinoma (HCC) tissue.
|
29906748 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we characterized CSCs in primary hepatocellular carcinoma (HCC) and identified CD133 as a CSC cell-surface marker.
|
30382122 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we revealed that the expression of liver cancer stem cell marker CD133 was also significantly increased in the residual hepatocellular carcinoma cells after RFA treatment in vivo, and was positively correlated with LC3B protein expression. iRFA also promoted CD133 protein expression in Huh-7 and SMMC7721 cell lines in vitro.
|
29749472 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 is served as a key biomarker to identify and characterize this subpopulation of cells in hepatocellular carcinoma (HCC).
|
29119708 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
|
29534065 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Annexin A3 (ANXA3) could induce progression of hepatocellular carcinoma (HCC) via promoting stem cell traits of CD133-positive cells.
|
29626309 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM<sup>+</sup>CD133<sup>-</sup>) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1-60 µM) of LDL-DHA nanoparticles for 0-72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL-DHA nanoparticles for 3 days.
|
30069818 |
2018 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD133+/CD44+ subgroup sorting from HCC cell lines and HCC tissues was used to investigate the effects of OPN knockdown on stemness. iTRAQ and MedIP-sequencing were applied to detect the protein profile and epigenetic modification of CD133+/CD44+ subgroup with or without OPN knockdown.
|
30064482 |
2018 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HCC cell lines with a high level of CD133 expression overexpressed EGFR, which is overexpressed in approximately 70% of conventional HCCs.
|
28034805 |
2017 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although less cytotoxic, the free ligand inhibits the surface marker CD133 expression in hepatocarcinoma cells, and in HT-29 colon carcinoma.
|
28358339 |
2017 |